177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Public ClinicalTrials.gov record NCT07189871. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT07189871
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Radiopharm Theranostics, Ltd
- Industry
- Enrollment
- 61 participants
Conditions and interventions
Conditions
- Castration-Resistant Prostate Cancer (CRPC)
- Cervical Cancer
- Colorectal Cancer
- Endometrial Cancer
- Esophageal Squamous Cell Carcinoma (ESCC)
- Head &Amp; Neck Squamous Cell Carcinoma (HNSCC)
- NSCLC (Non-small Cell Lung Cancer)
- Ovarian Cancer
- Small Cell Lung Cancer (SCLC )
- TNBC, Triple Negative Breast Cancer
Interventions
- 177Lu-BetaBart Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 22, 2026
- Primary completion
- Nov 30, 2027
- Completion
- Nov 30, 2027
- Last update posted
- Mar 26, 2026
2026 – 2027
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dothan Hematology & Oncology | Dothan | Alabama | 36303 | Recruiting |
| BAMF Health | Grand Rapids | Michigan | 49503 | Recruiting |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | Recruiting |
| XCancer | Omaha | Nebraska | 68130 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07189871, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07189871 live on ClinicalTrials.gov.